CoChat
Sign Up
Cited by 151Iron Metabolism and DisordersNeurological diseases and metabolismHemoglobinopathies and Related Disorders

The DOI matches its Crossref record; 121 of the 123 references it cites were found in a registry or an index.

Ferroportin disease: pathogenesis, diagnosis and treatment

Open access
Pietrangelo, Antonello·2017·Haematologica
DOI 10.3324/haematol.2017.170720PMC PMC5709096
Open this paper in CoChat — free account

Abstract

Ferroportin Disease (FD) is an autosomal dominant hereditary iron loading disorder associated with heterozygote mutations of the ferroportin-1 (FPN) gene. It represents one of the commonest causes of genetic hyperferritinemia, regardless of ethnicity. FPN1 transfers iron from the intestine, macrophages and placenta into the bloodstream. In FD, loss-of-function mutations of FPN1 limit but do not impair iron export in enterocytes, but they do severely affect iron transfer in macrophages. This leads to progressive and preferential iron trapping in tissue macrophages, reduced iron release to serum transferrin (i.e. inappropriately low transferrin saturation) and a tendency towards anemia at menarche or after intense bloodletting. The hallmark of FD is marked iron accumulation in hepatic Kupffer cells. Numerous FD-associated mutations have been reported worldwide, with a few occurring in different populations and some more commonly reported (e.g. Val192del, A77D, and G80S). FPN1 polymorphisms also represent the gene variants most commonly responsible for hyperferritinemia in Africans. Differential diagnosis includes mainly hereditary hemochromatosis, the syndrome commonly due to either HFE or TfR2, HJV, HAMP, and, in rare instances, FPN1 itself. Here, unlike FD, hyperferritinemia associates with high transferrin saturation, iron-spared macrophages, and progressive parenchymal cell iron load. Abdominal magnetic resonance imaging (MRI), the key non-invasive diagnostic tool for the diagnosis of FD, shows the characteristic iron loading SSL triad (spleen, spine and liver). A non-aggressive phlebotomy regimen is recommended, with careful monitoring of transferrin saturation and hemoglobin due to the risk of anemia. Family screening is mandatory since siblings and offspring have a 50% chance of carrying the pathogenic mutation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2017.170720

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Biology of ferroportin and postulated pathobiology of Ferroportin Disease (FD). (A) Structure-function relationship of iron-export ferroportin activity.39 (B) Putative mechanisms of hepcidin binding to FPN and its degradation.39 (C) Postulated basis for FD. (Upper panel) In cells undergoing relatively low iron flux, such as enterocytes, the product of the FPN wild-type allele is able to reach the plasma membrane and export iron. For clarity, mutated FPN1 was not depicted at the cell surface: based on previous in vitro work, it has been postulated that some mutant FPN1 can still reach the cell surface and preserve some iron-transport competence, but this is still controversial. (Lower panel) In cells undergoing high iron turnover, such as macrophages, increased requests for iron export impose high demands on FPN traffic leading to a ‘traffic jam’ within the endocytic/plasmamembrane and degradation compartments and inappropriately low wild-type allele product targeting to the cell membrane.54 (D) Postulated effect of FPN mutations that affect formation of the intracellular gate and access to the iron binding site.39
Figure 1. Biology of ferroportin and postulated pathobiology of Ferroportin Disease (FD). (A) Structure-function relationship of iron-export ferroportin activity.39 (B) Putative mechanisms of hepcidin binding to FPN and its degradation.39 (C) Postulated basis for FD. (Upper panel) In cells undergoing relatively low iron flux, such as enterocytes, the product of the FPN wild-type allele is able to reach the plasma membrane and export iron. For clarity, mutated FPN1 was not depicted at the cell surface: based on previous in vitro work, it has been postulated that some mutant FPN1 can still reach the cell surface and preserve some iron-transport competence, but this is still controversial. (Lower panel) In cells undergoing high iron turnover, such as macrophages, increased requests for iron export impose high demands on FPN traffic leading to a ‘traffic jam’ within the endocytic/plasmamembrane and degradation compartments and inappropriately low wild-type allele product targeting to the cell membrane.54 (D) Postulated effect of FPN mutations that affect formation of the intracellular gate and access to the iron binding site.39CC BY-NC · PubMed Central
Figure 2. The basis for abnormal iron transfer into the bloodstream in Ferroportin Disease as opposed to FPN-associated hereditary hemochromatosis.
Figure 2. The basis for abnormal iron transfer into the bloodstream in Ferroportin Disease as opposed to FPN-associated hereditary hemochromatosis.CC BY-NC · PubMed Central
Figure 3. The different stages and outcomes of “iron retention” in Ferroportin Disease versus “iron accumulation” in FPN1-associated hemochromatosis (HC). Liver histology pictures are reproduced with the permission of Sabelli et al.54
Figure 3. The different stages and outcomes of “iron retention” in Ferroportin Disease versus “iron accumulation” in FPN1-associated hemochromatosis (HC). Liver histology pictures are reproduced with the permission of Sabelli et al.54CC BY-NC · PubMed Central
Figure 4. Diagnostic algorithm for Ferroportin Disease and hereditary hyperferritinemia. ACD/AI: anemia of chronic disease/anemia of inflammation. *Gaucher disease may present with or without siderosis depending on the disease stage. **Advanced ACD/AI may also present with siderosis at MRI (usually spleen and bone marrow).
Figure 4. Diagnostic algorithm for Ferroportin Disease and hereditary hyperferritinemia. ACD/AI: anemia of chronic disease/anemia of inflammation. *Gaucher disease may present with or without siderosis depending on the disease stage. **Advanced ACD/AI may also present with siderosis at MRI (usually spleen and bone marrow).CC BY-NC · PubMed Central
Figure 5. Abdominal magnetic resonance imaging (MRI) pattern of Ferroportin Disease (FD). MRI scans. T2*-weighted gradient-echo sequences were used to detect iron accumulation. (A) Normal subject. (B) FD. (C) FD after completion of phlebotomy program (note that excess iron is still detectable in the liver and spine in spite of normal serum ferritin and transferrin saturation levels). (D) Ferroportin-associated hereditary hemochromatosis: iron accumulation involves only the liver and spares the spleen and spine (arrows).
Figure 5. Abdominal magnetic resonance imaging (MRI) pattern of Ferroportin Disease (FD). MRI scans. T2*-weighted gradient-echo sequences were used to detect iron accumulation. (A) Normal subject. (B) FD. (C) FD after completion of phlebotomy program (note that excess iron is still detectable in the liver and spine in spite of normal serum ferritin and transferrin saturation levels). (D) Ferroportin-associated hereditary hemochromatosis: iron accumulation involves only the liver and spares the spleen and spine (arrows).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 123 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Pietrangelo, A.
Affiliations
University of Modena and Reggio Emilia (IT)
Corresponding author
Pietrangelo, Antonello
ORCID
Pietrangelo, Antonello
Venue
Haematologica
Publisher
Ferrata Storti Foundation (Haematologica)
Published
2017-11-03
Volume
102
Issue
12
Pages
1972-1984
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
DOI
10.3324/haematol.2017.170720
PMC
PMC5709096
OpenAlex
W2766930181
Cited by
151
References
123
Citations by year
2026: 12 · 2025: 22 · 2024: 14 · 2023: 17 · 2022: 10 · 2021: 28 · 2020: 23 · 2019: 7 · 2018: 16 · 2017: 1
FWCI
9.91
Type
journal article
Language
en
Open access
Locations
  • Haematologica (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Keywords
ferroportin disease, ferroportin 1, hereditary iron overload, hyperferritinemia, transferrin saturation, Kupffer cells, phlebotomy, family screening
MeSH terms
Ferroportin, Humans, Kupffer Cells, Mutation, Phlebotomy, Iron Overload, Cation Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review